UTRECHT, The Netherlands, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage
immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of John Crowley as
Chief Financial Officer. In this position, Mr. Crowley will lead Merus’ finance function reporting to Dr. Ton Logtenberg, Chief
Executive Officer of Merus. He will be based in Cambridge, Massachusetts. Former Chief Financial Officer, Ms. Shelley Margetson has
been elevated to Chief Operating Officer.
“John brings strong financial acumen, global biotech operational experience and leadership capabilities to Merus during an
important time in the Company’s evolution,” said Dr. Logtenberg. “We look forward to his contributions as a member of the executive
leadership team as we expand our US footprint, and execute our development strategy for our Biclonics platform.”
Dr. Logtenberg continued, “I would also like to thank Shelley for her exceptional performance as our Chief Financial Officer and
her critical role in our successful initial public offering on the NASDAQ exchange last May. Her high degree of performance and
commitment fully justifies her new role.”
“I am excited to join Merus at its current phase of development and to work closely with its global executive team,” said Mr.
Crowley. “The Company has made significant progress in advancing its two lead compounds into the clinic, establishing
collaborations with international companies and successfully completing a public offering to support the development of its
clinical programs. I look forward to helping to navigate the Company towards its next milestones.”
Mr. Crowley has over 20 years of global biotechnology financial and operational experience. Most recently, he served as
Corporate Senior Vice President, Corporate Controller and Chief Accounting Officer of Charles River Laboratories. Previously, he
served as the Vice President, Corporate Controller and Chief Accounting Officer at Ironwood Pharmaceuticals and held senior
corporate finance positions at Vertex Pharmaceuticals and Sunovian Pharmaceuticals, Inc. Mr. Crowley is a Certified Public
Accountant and graduated Summa Cum Laude from Babson College with B.S. degrees in both Economics and Accountancy.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics,
referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes
and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as
long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2
clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate,
MCLA-117, is being developed in a Phase 1/ 2 clinical trial in patients with acute myeloid leukemia. The Company also has a
pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to
cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics®
designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements regarding the impact of management personnel on our business,
our expansion into the United States and execution of our business strategy, and the treatment potential for bispecific antibody
candidates.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not
currently profitable and may never become profitable; our need for additional funding, which may not be available and which may
require us to restrict out operations or require us to relinquish rights to our technologies or bispecific antibody candidates;
potential delays in regulatory approval, which would impact the ability to commercialize our product candidates and affect our
ability to generate revenue; the unproven approach to therapeutic intervention of our Biclonics® technology; potential difficulties
in validating and developing companion diagnostics, which could harm our development strategy; our limited operating history;
economic, political, regulatory and other risks involved with international operations; exchange rate fluctuations or abandonment
of the euro currency; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the
unpredictable nature of our early stage development efforts for marketable drugs; potential adverse public reaction to the use of
cancer immunotherapies; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory
approvals; our potential exposure to costly and damaging liability claims; post-marketing restrictions or withdrawal from the
market; failure to obtain marketing approval internationally; compliance with environmental, health, and safety laws and
regulations; anti-kickback, fraud, abuse, and other healthcare laws and regulations exposing us to potential criminal sanctions;
recently enacted or future legislation; failure to compete successfully against other drug companies; potential competition from
other drug companies if we fail to obtain orphan drug designation or maintain orphan drug exclusivity for our products; the
possibility that governmental authorities and health insurers may not establish adequate reimbursement levels and pricing policies
to support our products; the potential failure of our product candidates to be accepted on the market by the medical community; our
lack of experience selling, marketing and distributing products and our lack of internal capability to do so; potential competition
from biosimilars; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not
perform satisfactorily; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our
development and commercialization efforts; protection of our proprietary technology; our patents being found invalid or
unenforceable; potential lawsuits for infringement of third-party intellectual property; adequate protection of our trademarks; our
potential failure to obtain extensions of the terms of patents covering our products; potential difficulties protecting our
intellectual property rights in certain jurisdictions; changes in United States patent law; protection of the confidentiality of
our trade secrets; claims asserting that we or our employees misappropriated a third-party’s intellectual property or otherwise
claiming ownership of what we regard as our intellectual property; compliance with patent regulations; potential system failures;
our ability to attract and retain key personnel; managing our growth could result in difficulties; the price of our common stock
may fluctuate substantially; certain of our shareholders and members of our management board own a majority of our outstanding
shares and exercise significant control over us; a significant portion of our total outstanding shares are eligible to be sold into
the market; provisions of our Articles of Association or Dutch corporate law might deter favorable acquisition bids for us or
prevent a beneficial change of control; we may lose our foreign private issuer status and incur significant expenses as a result;
and unfavorable or lacking analyst research or reports might cause the price of our common shares to decline.
These and other important factors discussed under the caption “Risk Factors” in our final prospectus filed with the Securities
and Exchange Commission, or SEC, on May 20, 2016 relating to our Registration Statement on Form F-1, and our other reports filed
with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we
may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if
subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views
as of any date subsequent to the date of this press release.
Contacts: Merus N.V. Shelley Margetson – s.margetson@merus.nl +31 (0)30 253 8800 Argot Partners Kimberly Minarovich – kimberly@argotpartners.com 1-212-600-1902
